The verification study of improvements in cognitive functions: A randomized double-blind placebo-controlled trial
- Conditions
- Healthy Japanese adult people
- Registration Number
- JPRN-UMIN000031757
- Lead Sponsor
- ORTHOMEDICO Inc.
- Brief Summary
Sekikawa T, Kizawa Y, Li Y, Takara T. Cognitive Function Improvement with Astaxanthin Intake: A Randomized, Double-Blind, Placebo-Controlled Study. Pharmacometrics 2019; 97(1/2): 1-13
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 44
Not provided
1. At least one previous medical history of malignant tumor, heart failure or myocardial infarction 2. Undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver failure, kidney failure, cerebrovascular disease, rheumatism, diabetes mellitus, dyslipidemia, hypertension or any other chronic diseases 3. Subjects who have dementia 4. Subjects who have mental health issues such as depression disorder, attention deficit/hyperactivity disorder (ADHD), or other issues 5. Currently taking medications (include herbal medicines), "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage 6. Subjects who take supplements related to improving cognitive functions, such as docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), ginkgo leaf extract, tocotrienol, astaxanthin, gamma-aminobutyric acid (GABA), and phosphatidylserine in daily 7. Subjects who are allergic to medicines and/or the test food related products 8. Subjects who are pregnant, lactation, and planning to become pregnant 9. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial 10. Subjects who are judged as ineligible to participate in the study by the physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method